Moreover, activation of CDK–Rb–E2F signaling has often been associated with endocrine resistance; for this reason, CDK4/6 inhibitors, such as palbociclib, are investigated in clinical trials in ER+ cancer. The gene discussed is CDK4; the disease is cancer.